The 10-year projections demonstrate market potential for patient-owned healthcare, not immediate expectations. These projections illustrate the scale of transformation possible when patients gain collective control over their health data and care decisions, creating entirely new revenue streams and market dynamics.

The current bridge funding ask of $10K-50K from 5 selected investors will be used to demonstrate this scaling potential over the next 4-6 months. Specific bridge milestones include:

• Working demo for data platform
• Chronic care management pilot and payer credentialing
• LOI from pharma company
• Cohort referral from oncologist collaboration
• Data contribution from 100+ patients

Successfully hitting these milestones positions CEtHI for Series A funding at significantly higher valuation, providing bridge investors with substantial upside while limiting their exposure during the proof-of-concept phase.

CEtHI distinguishes between incremental business improvement and fundamental market transformation. Traditional metrics become relevant once the proof-of-concept for healthcare system replacement is established. The current phase focuses on building infrastructure and culture that enables new forms of value creation outside existing system constraints.

Current ask is $10K-50K bridge funding using a SAFE structure to prove revenue model and reach Series A readiness. Bridge milestones will be achieved over 4-6 months, establishing foundation for Series A with demonstrated market validation. This provides early investors with potential upside while limiting exposure to early-stage risks.

For patients to have real leverage against the healthcare system, they need collective bargaining power through shared data ownership and coordinated decision-making. Individual patients get dismissed, but patient communities with collective data and shared IP have leverage. Traditional corporate structures mean a company controls patient data even if patients generated it. Web3 infrastructure enables genuine community ownership where patients collectively control research priorities and data usage without intermediary capture. This creates the market power needed to make providers adapt to patient-driven care within the mainstream healthcare system.

Current platforms help providers analyze data better, but patients still can't access safe off-label treatments, still wait decades for research to reach care, and still get dismissed when asking for non-standard testing. CEtHI enables patients to collectively try safe drug combinations, generate real-world evidence faster than traditional trials, and make their own care decisions with proper education and support. The $180B alternative medicine market shows patients will create their own solutions when mainstream medicine fails them - CEtHI provides that infrastructure within scientific frameworks.

While both work in precision oncology, companies like Tempus must overcome significant regulatory hurdles to provide patients with comprehensive testing, limiting what information they can legally deliver. CEtHI enables patients to access scientifically vetted, research-grade data collection methodologies at cost-effective prices without regulatory constraints designed to prove clinical benefit - constraints that are too restrictive when the goal is simply information gathering. Patients inherently want comprehensive information about themselves for real-world evidence generation, even when not immediately actionable or part of standard care. The fundamental difference is regulatory freedom: provider-controlled platforms are constrained by clinical approval requirements, while patient-owned infrastructure allows access to the full scope of available scientific methodologies.

The system's fundamental economic structure makes reform impossible. Providers are reimbursed for volume, not outcomes, creating perverse incentives against precision care. Insurance models depend on population-based risk pooling that inherently conflicts with individualized treatment. Regulatory agencies are captured by incumbents who use "safety" requirements as barriers to innovation. Medical licensing creates legal monopolies that prevent patient-directed care models. These aren't bugs to be fixed - they're the core revenue mechanisms that fund the entire healthcare establishment. Meanwhile, technology convergence now enables patient-controlled precision medicine for the first time. The $180B alternative medicine market proves patients will create their own markets when mainstream medicine fails them. Economic pressure and regulatory lag create an unstable system ready for replacement. Patient empowerment is irreversible once experienced.

Value-based care still operates within the provider-controlled paradigm where "value" is defined by population-level metrics that may not align with individual patient priorities. A patient facing terminal cancer may value experimental treatments and quality-of-life measures that don't appear in value-based contracts. It doesn't give patients control over what constitutes "value" for their specific situation, nor does it address innovation suppression or regulatory capture. Value-based care is incremental reform that preserves the fundamental power structure while making the existing system slightly more efficient.

Investors own equity in CEtHI the infrastructure company, not the patient communities themselves. CEtHI generates revenue through platform fees, technology licensing to patient DAOs, data infrastructure services, and revenue sharing from pharma partnerships that patient communities approve. As more patient communities form and the platform scales, CEtHI's infrastructure becomes more valuable. Patient DAOs remain independent and make their own decisions, while CEtHI provides the technology and support services they need. This dual structure allows genuine patient ownership while creating sustainable returns for infrastructure investors.

CEtHI follows a detailed phase roadmap that progresses from individual services to community formation to distributed infrastructure. Each phase builds culture and infrastructure for the next while generating revenue and operating within existing regulatory frameworks using licensed professionals and established chronic care management. Patient empowerment focuses on safe, off-label uses of approved drugs and real-world evidence generation, not bypassing safety standards. This phased approach allows safety validation and regulatory compliance while building toward healthcare transformation.